PolyPid Ltd. will present at the Oppenheimer Healthcare Conference, discussing its surgical outcome-improving technologies and ongoing clinical trials.
Quiver AI Summary
PolyPid Ltd., a late-stage biopharma company focused on enhancing surgical outcomes, announced that its management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which will be held virtually from February 11-12, 2025. The presentation will be available on-demand starting February 12 at 11:20 AM Eastern Time and will remain accessible for one year. Additionally, PolyPid's management will engage in one-on-one investor meetings during the event. The company is known for its proprietary PLEX technology, which allows for controlled release of therapeutics, and its lead product candidate, D-PLEX100, is undergoing Phase 3 trials for preventing surgical site infections. PolyPid is also exploring OncoPLEX for the treatment of solid tumors, including glioblastoma, in preclinical stages. For more information, visit their website.
Potential Positives
- PolyPid is participating in the prestigious Oppenheimer 35th Annual Healthcare Life Sciences Conference, which enhances its visibility in the investment community.
- The presentation will be available on-demand, extending the reach of PolyPid's messaging to a broader audience for a full year.
- The management team will engage in one-on-one investor meetings, providing an opportunity to build relationships and potentially attract new investment.
- PolyPid's lead product candidate, D-PLEX100, is in a late-stage Phase 3 clinical trial, indicating significant progress in its development pipeline focused on improving surgical outcomes.
Potential Negatives
- The press release highlights that PolyPid is still in the late-stage clinical trials for its lead product candidate, which may indicate delays in bringing the product to market.
- The mention of only one active clinical trial (D-PLEX100) raises concerns about the company's product pipeline and its ability to diversify its offerings.
- Being a late-stage biopharma company in a highly competitive sector may pose significant risks if their products do not achieve regulatory approval or market acceptance.
FAQ
What is the date of the Oppenheimer 35th Annual Healthcare Conference?
The conference is scheduled to take place from February 11 to 12, 2025.
How can I access PolyPid's presentation?
PolyPid's presentation will be available on-demand beginning February 12, 2025, for 365 days on the conference platform.
What is PolyPid’s lead product candidate?
PolyPid’s lead product candidate is D-PLEX100, currently in Phase 3 trials for preventing surgical site infections.
How does PolyPid’s PLEX technology work?
PLEX technology enables controlled, prolonged-release of therapeutics, ensuring precise drug delivery over extended periods.
Who can I contact for investor meetings at the conference?
Investors interested in meetings should contact their Oppenheimer representative for arrangements.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PYPD Hedge Fund Activity
We have seen 5 institutional investors add shares of $PYPD stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROSALIND ADVISORS, INC. added 262,368 shares (+62.9%) to their portfolio in Q3 2024, for an estimated $902,545
- AIGH CAPITAL MANAGEMENT LLC added 200,422 shares (+41.8%) to their portfolio in Q3 2024, for an estimated $689,451
- STONEPINE CAPITAL MANAGEMENT, LLC added 138,504 shares (+inf%) to their portfolio in Q3 2024, for an estimated $476,453
- DAFNA CAPITAL MANAGEMENT LLC added 123,651 shares (+66.9%) to their portfolio in Q3 2024, for an estimated $425,359
- ADAR1 CAPITAL MANAGEMENT, LLC removed 10,048 shares (-9.7%) from their portfolio in Q3 2024, for an estimated $34,565
- TD WATERHOUSE CANADA INC. added 781 shares (+inf%) to their portfolio in Q3 2024, for an estimated $2,686
- UBS GROUP AG removed 415 shares (-17.2%) from their portfolio in Q3 2024, for an estimated $1,427
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025.
Oppenheimer 35 th Annual Healthcare Life Sciences Conference
PolyPid’s presentation will be available on-demand beginning on Wednesday, February 12, 2025 at 11:20 AM Eastern Time and for 365 days after via the conference platform or using the following link .
The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid at the conference should contact their Oppenheimer representative.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX 100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn .
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
[email protected]
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
[email protected]